13168 related articles for article (PubMed ID: 10870051)
1. Analysis of therapeutic and immunologic effects of R(24) anti-GD3 monoclonal antibody in 37 patients with metastatic melanoma.
Kirkwood JM; Mascari RA; Edington HD; Rabkin MS; Day RS; Whiteside TL; Vlock DR; Shipe-Spotloe JM
Cancer; 2000 Jun; 88(12):2693-702. PubMed ID: 10870051
[TBL] [Abstract][Full Text] [Related]
2. Antibody responses in melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2.
Foon KA; Sen G; Hutchins L; Kashala OL; Baral R; Banerjee M; Chakraborty M; Garrison J; Reisfeld RA; Bhattacharya-Chatterjee M
Clin Cancer Res; 1998 May; 4(5):1117-24. PubMed ID: 9607568
[TBL] [Abstract][Full Text] [Related]
3. Administration of R24 monoclonal antibody and low-dose interleukin 2 for malignant melanoma.
Soiffer RJ; Chapman PB; Murray C; Williams L; Unger P; Collins H; Houghton AN; Ritz J
Clin Cancer Res; 1997 Jan; 3(1):17-24. PubMed ID: 9815532
[TBL] [Abstract][Full Text] [Related]
4. Phase I evaluation of a combination of monoclonal antibody R24 and interleukin 2 in patients with metastatic melanoma.
Bajorin DF; Chapman PB; Wong G; Coit DG; Kunicka J; Dimaggio J; Cordon-Cardo C; Urmacher C; Dantes L; Templeton MA
Cancer Res; 1990 Dec; 50(23):7490-5. PubMed ID: 2253196
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.
Ribas A; Camacho LH; Lopez-Berestein G; Pavlov D; Bulanhagui CA; Millham R; Comin-Anduix B; Reuben JM; Seja E; Parker CA; Sharma A; Glaspy JA; Gomez-Navarro J
J Clin Oncol; 2005 Dec; 23(35):8968-77. PubMed ID: 16204013
[TBL] [Abstract][Full Text] [Related]
6. Phase IB trial of chimeric antidisialoganglioside antibody plus interleukin 2 for melanoma patients.
Albertini MR; Hank JA; Schiller JH; Khorsand M; Borchert AA; Gan J; Bechhofer R; Storer B; Reisfeld RA; Sondel PM
Clin Cancer Res; 1997 Aug; 3(8):1277-88. PubMed ID: 9815810
[TBL] [Abstract][Full Text] [Related]
7. Biologic and immunomodulatory events after CTLA-4 blockade with ticilimumab in patients with advanced malignant melanoma.
Reuben JM; Lee BN; Li C; Gomez-Navarro J; Bozon VA; Parker CA; Hernandez IM; Gutierrez C; Lopez-Berestein G; Camacho LH
Cancer; 2006 Jun; 106(11):2437-44. PubMed ID: 16615096
[TBL] [Abstract][Full Text] [Related]
8. Immunization of melanoma patients with BEC2 anti-idiotypic monoclonal antibody that mimics GD3 ganglioside: enhanced immunogenicity when combined with adjuvant.
McCaffery M; Yao TJ; Williams L; Livingston PO; Houghton AN; Chapman PB
Clin Cancer Res; 1996 Apr; 2(4):679-86. PubMed ID: 9816218
[TBL] [Abstract][Full Text] [Related]
9. Sequential immunization of melanoma patients with GD3 ganglioside vaccine and anti-idiotypic monoclonal antibody that mimics GD3 ganglioside.
Chapman PB; Wu D; Ragupathi G; Lu S; Williams L; Hwu WJ; Johnson D; Livingston PO
Clin Cancer Res; 2004 Jul; 10(14):4717-23. PubMed ID: 15269144
[TBL] [Abstract][Full Text] [Related]
10. Anti-melanoma effects of R24, a monoclonal antibody against GD3 ganglioside.
Nasi ML; Meyers M; Livingston PO; Houghton AN; Chapman PB
Melanoma Res; 1997 Aug; 7 Suppl 2():S155-62. PubMed ID: 9578432
[TBL] [Abstract][Full Text] [Related]
11. A phase II trial comparing five dose levels of BEC2 anti-idiotypic monoclonal antibody vaccine that mimics GD3 ganglioside.
Chapman PB; Williams L; Salibi N; Hwu WJ; Krown SE; Livingston PO
Vaccine; 2004 Jul; 22(21-22):2904-9. PubMed ID: 15246627
[TBL] [Abstract][Full Text] [Related]
12. Natural killer receptors on CD8 T cells and natural killer cells from different HLA-C phenotypes in melanoma patients.
Campillo JA; Martínez-Escribano JA; Moya-Quiles MR; Marín LA; Muro M; Guerra N; Parrado A; Campos M; Frías JF; Minguela A; García-Alonso AM; Alvarez-López MR
Clin Cancer Res; 2006 Aug; 12(16):4822-31. PubMed ID: 16914567
[TBL] [Abstract][Full Text] [Related]
13. Dendritoma vaccination combined with low dose interleukin-2 in metastatic melanoma patients induced immunological and clinical responses.
Wei Y; Sticca RP; Holmes LM; Burgin KE; Li J; Williamson J; Evans L; Smith SJ; Stephenson JJ; Wagner TE
Int J Oncol; 2006 Mar; 28(3):585-93. PubMed ID: 16465362
[TBL] [Abstract][Full Text] [Related]
14. Expansion of natural killer cells in mice transgenic for IgM antibody to ganglioside GD2: demonstration of prolonged survival after challenge with syngeneic tumor cells.
Kawashima I; Yoshida Y; Taya C; Shitara H; Yonekawa H; Karasuyama H; Tada N; Furukawa K; Tai T
Int J Oncol; 2003 Aug; 23(2):381-8. PubMed ID: 12851687
[TBL] [Abstract][Full Text] [Related]
15. Melanoma antibodies: specificity and interaction with melanoma and cytotoxic T-cells.
Dippold WG; Knuth A; Meyer zum Büschenfelde KH
Behring Inst Mitt; 1984 May; (74):14-8. PubMed ID: 6332614
[TBL] [Abstract][Full Text] [Related]
16. Eastern cooperative group trial of interferon gamma in metastatic melanoma: an innovative study design.
Schiller JH; Pugh M; Kirkwood JM; Karp D; Larson M; Borden E
Clin Cancer Res; 1996 Jan; 2(1):29-36. PubMed ID: 9816086
[TBL] [Abstract][Full Text] [Related]
17. Light chain variants of an IgG3 anti-GD3 monoclonal antibody and the relationship among avidity, effector functions, tumor targeting, and antitumor activity.
Chapman PB; Lonberg M; Houghton AN
Cancer Res; 1990 Mar; 50(5):1503-9. PubMed ID: 2105840
[TBL] [Abstract][Full Text] [Related]
18. Phase I trial of the murine monoclonal anti-GD2 antibody 14G2a in metastatic melanoma.
Saleh MN; Khazaeli MB; Wheeler RH; Dropcho E; Liu T; Urist M; Miller DM; Lawson S; Dixon P; Russell CH
Cancer Res; 1992 Aug; 52(16):4342-7. PubMed ID: 1643631
[TBL] [Abstract][Full Text] [Related]
19. Potentiation of lymphocyte responses by monoclonal antibodies to the ganglioside GD3.
Hersey P; Schibeci SD; Townsend P; Burns C; Cheresh DA
Cancer Res; 1986 Dec; 46(12 Pt 1):6083-90. PubMed ID: 3022915
[TBL] [Abstract][Full Text] [Related]
20. The immune response to disialoganglioside GD3 vaccination in normal dogs: a melanoma surface antigen vaccine.
Milner RJ; Salute M; Crawford C; Abbot JR; Farese J
Vet Immunol Immunopathol; 2006 Dec; 114(3-4):273-84. PubMed ID: 17027091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
